cp wire

CP Wire Articles

Sponsored: New AI Business Analysis Platform Can Aid Pharma Decision Making
Data analytics startup Outlier, following its ... read more
Wed, 10/10/18 - 12:01 pm
admin
Release: Outlier Introduces AI Powered Automated Business Analysis Platform
Delivers industry’s first cross-platform Root Cause Analysis feature and broadens integration support to include Amazon Redshift Spectrum, Apache Druid & Google Ads
... read more
Wed, 10/10/18 - 11:34 am
admin
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
  • Empagliflozin was estimated to extend life expectancy by 1 to 4.5 years on average
  • In Sept of 2018 it was announced that the class of drugs that includes empagliflozin was associated... read more
Wed, 10/10/18 - 10:08 am
admin
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
  • Ozanimod had a "beneficial effect" on cognitive processing speed
  • The drug also reduced relapse rates and MRI lesions compared to Avonex
  • Ozanimod is also in development for... read more
Wed, 10/10/18 - 09:50 am
admin
[release] Firalis and Celemics announce an agreement for the commercialization of a unique proprietary long non- coding RNA (lncRNA) panel, FiMICS®

Firalis S.A. (“Firalis”), a Huningue based developer and provider of biomarker products and bioanalytical... read more

Tue, 10/9/18 - 11:44 am
admin
FDA Releases New Draft Guidance to Aid Development of Generic Versions of Complex Drugs

On 10/9/18 FDA Commissioner, Scott Gottlieb MD, announced a series of guidance documents meant to advance the... read more

Tue, 10/9/18 - 10:13 am
admin
Myriad and Pfizer Sign Deal to Commercialize Companion Diagnostic

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that it has signed a commercialization plan with Pfizer Inc.  The plan is under an existing... read more

Tue, 10/9/18 - 09:44 am
admin
Rgenix Banks $40 Million in Series C Round

Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced that it has raised $40 million in a Series C financing... read more

Tue, 10/9/18 - 09:23 am
admin
Altimmune Raises $25 million With Direct Offering
  • So far in September and October of 2018 Altimmune has raised over $60 million
  • On 10/6/18 the company presented data that showed that the company's NasoVAX was well-tolerated and... read more
Mon, 10/8/18 - 10:46 am
admin
Veracyte Presents Data Demonstrating Afirma's Success in Reducing Unnecessary Surgery
  • At one site, the surgery rate was reduced by more than 50%
  • Veracyte claims to have removed an estimated $800 million in surgery costs from the healthcare system


... read more

Mon, 10/8/18 - 10:08 am
admin
[release] Following approval in Sweden, Lobsor eyes US entry for new Lecigon treatment for Parkinson’s Disease
Uppsala, October 8, 2018. Lobsor Pharmaceuticals AB, a privately held Swedish company based in Uppsala today announced that Lecigon®, a new therapeutic system for symptomatic treatment... read more
Mon, 10/8/18 - 10:08 am
admin
Bacteriophage Company AmpliPhi Presents Positive Data on Expanded Access Program for Serious S. aureus Infections
  • 10 of 12 patients achieved treatment success
  • AB-SA01 was well tolerated with no adverse events attributable to AB-SA01
  • Initial gene expression data indicate that... read more
Mon, 10/8/18 - 09:49 am
admin
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
  • Thyroid cancer is the most rapidly increasing cancer diagnosis in the US with incidence tripling over the last 30 years
  • Cabometyx is approved for renal cell carcinoma and... read more
Mon, 10/8/18 - 09:25 am
admin
Aytu Prices Upcoming Public Offering at 13.2 Million
  • The company currently markets Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T")
  • Aytu also recently acquired... read more
Fri, 10/5/18 - 10:24 am
admin
Amicus Announces Positive Results for AT-GAA in Pompe Disease
  • Muscle funtion improved in 17 of 19 patients at month 12
  • Treatment with AT-GAA resulted in persistent and durable reductions in key biomarkers of muscle damage across all patient... read more
Fri, 10/5/18 - 09:46 am
admin
EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder
  • LentiGlobin has Orphan Drug status in Europe and the US
  • It has also been granted an accelerated assessment in Europe and Breakthrough Therapy designation in the US
  • ... read more
Fri, 10/5/18 - 09:18 am
admin
Microbiome Report for Week Ending 9/29/18

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief... read more

Thu, 10/4/18 - 02:59 pm
admin
Vaxart Stock Soars on Oral Flu Vaccine Results

Vaxart Stock is up over 165% after after the biotechnology company announced results from a phase 2 trial that its oral flu vaccine performed better than Sanofi's Fluzone.

"These latest... read more

Thu, 10/4/18 - 09:57 am
admin
Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors
  • SNX-5422 has been granted Orphan Drug Status for neuroendocrine tumors by the FDA
  • SNX-5422 is an orally active Hsp90 inhibitor that has provided durable clinical responses in open... read more
Thu, 10/4/18 - 09:28 am
admin
Ophthotech Completes Recruitment for Ph IIb Trial of Zimura for Geographic Atrophy Secondary to Dry AMD
  • Zimura also being studied in wet AMD,  idiopathic polypoidal choroidal vasculopathy, and  Stargardt disease
  • Initial Top-line Zimura Geographic Atrophy Data Expected in the Fourth... read more
Thu, 10/4/18 - 09:17 am
admin

Pages



current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.